Can Hims & Hers Health (HIMS) Stock Reach $40?

Key Takeaways

• Selected price target: $40 per share, roughly 25–30% above recent trading levels near $31 and the current high end of Wall Street's price-target range.
• Bullish case: Rapid revenue growth, a branded GLP-1 partnership with Novo Nordisk (NVO), international expansion, and an emerging peptide opportunity.
• Key risks: Gross-margin compression, an ongoing FTC lawsuit over data-sharing practices, rising competition, and heavy insider selling.
• Key levels: The stock's 52-week range spans $13.74 to $65.30, leaving $40 as a psychological milestone well below the prior high but well above current support.
• Bottom line: $40 is plausible if margins stabilize and the GLP-1 transition succeeds, but it is not guaranteed and depends on execution and regulatory outcomes.

Why Investors Are Watching the $40 Level

Hims & Hers Health, Inc. (HIMS), a direct-to-consumer telehealth platform, has been one of the most volatile names in the healthcare sector. After peaking above $65 during a speculative run in weight-loss drug hype, shares collapsed and have recently traded near $31. That leaves $40 as a round-number milestone that sits almost exactly at the top of the current analyst price-target range, making it a natural question for investors: can HIMS climb back to $40?

The level is neither trivial nor out of reach. It would require a gain of roughly 25–30% from recent prices, a meaningful but not extreme move for a stock with HIMS's historical volatility. It also corresponds with the "Street-high" targets issued by several research firms, giving the figure a concrete anchor in public market discussion.

Company Overview

Hims & Hers operates a multi-specialty telehealth platform offering treatments across sexual health, hair loss, skin care, mental health, and weight management. Founded in 2017 and publicly listed in January 2021, the company uses a direct-to-consumer subscription model and has built a vertically integrated pharmacy network serving millions of subscribers across all 50 U.S. states and select international markets.

The weight-loss, or GLP-1, category has become the company's dominant growth driver and its largest source of investor debate. After the FDA ended shortages of certain branded drugs, Hims & Hers shifted away from higher-margin compounded medications toward branded products through a partnership with Novo Nordisk, a pivot that boosted revenue but squeezed profitability.

Current Market Position

The company's most recent quarterly report underscored both the opportunity and the challenge. Revenue grew about 40% year over year to roughly $753 million, beating estimates, and management raised its full-year revenue guidance to approximately $3.1 billion to $3.3 billion. However, the quarter swung to a substantial net loss, and gross margin fell to about 64% as the sales mix shifted toward lower-margin branded weight-loss drugs.

Technically, the stock remains far below its 52-week high of $65.30 and well above its low of $13.74. After a sharp selloff tied to an FTC lawsuit, shares rebounded strongly following a CNBC interview in which CEO Andrew Dudum projected that out-of-pocket GLP-1 costs could eventually fall to $40–$50 per month from $150–$200. That pricing promise, if realized, would be read as a path back toward margin recovery.

What Could Drive the Next Leg Higher

Several factors could support a move toward $40. The branded GLP-1 transition, while dilutive to margins in the short term, positions the company to grow a durable customer base using FDA-approved products with reduced regulatory risk. Cross-selling those customers into higher-margin categories such as hair care, skin care, and mental health is central to the long-term thesis.

International expansion, including the completed acquisition of the Eucalyptus telehealth platform, adds a new growth avenue. The emerging peptide market also offers optionality, though analysts generally caution that meaningful peptide revenue is unlikely before 2028. Improving credit-card spending data and a widening lead over competitors have already prompted several firms to raise targets.

What Could Prevent the Move

The obstacles are substantial. The Federal Trade Commission sued Hims & Hers in July 2026, alleging the company shared users' health data with Meta (META) and Snap (SNAP) despite privacy promises. The case remains unresolved and could impose financial or reputational costs.

Competition is intensifying, with Amazon (AMZN) expanding into hair-loss and weight-loss treatments and rival telehealth platforms vying for GLP-1 subscribers. Customer retention on branded oral Wegovy is a key concern, especially as subscription pricing steps up after introductory periods. Meanwhile, insider activity has shown significant net selling over the past year, which some investors read as a cautionary signal.

Analyst Opinions and Price Targets

Wall Street's consensus is cautious rather than enthusiastic, with an average price target near $30–32 and a "Hold" consensus. Individual targets span a wide range, from a low of roughly $21 to a high of $42, with firms such as Needham and Canaccord Genuity maintaining Buy ratings and targets at $42 and $40 respectively. Barclays recently trimmed its target to $35 while retaining an Overweight rating, citing margin pressure from growth investments.

This dispersion reflects genuine uncertainty. The bulls see a reaccelerating revenue story with a path to margin normalization; the bears see a still-unprofitable business facing legal and competitive headwinds. A move to $40 would require the stock to reach the top of the current analyst range, implying that the most constructive scenarios play out.

AI Daily Buy/Sell Signals

For traders seeking to monitor whether HIMS can sustain momentum toward its $40 price target, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to track changing conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on technical behavior, market conditions, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening alone.

Final Assessment

Reaching $40 is realistic but not assured. The strongest arguments in favor are the company's rapid revenue growth, its pivot to a regulatory-safe branded GLP-1 model, international expansion, and the prospect of margin recovery as pricing normalizes. The primary obstacles are the unresolved FTC litigation, continued gross-margin pressure, intensifying competition, and a still-unprofitable bottom line.

For HIMS to reach $40, investors would likely need to see several conditions converge: stabilization or improvement in gross margins, evidence of strong customer retention on branded weight-loss drugs, and a resolution or de-escalation of the FTC case. Until those signals appear, $40 remains a plausible upside scenario rather than a base case. Investors should monitor quarterly margin trends, subscriber metrics, and legal developments before drawing firm conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations